Optimalization of Nephroprotection Using N-Acetylcysteine

NACompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2005

Conditions
Chronic Kidney DiseaseProteinuria
Interventions
DRUG

ACC (N-acetylcysteine) 1200 mg

N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each

All Listed Sponsors
lead

Medical University of Gdansk

OTHER

NCT00572663 - Optimalization of Nephroprotection Using N-Acetylcysteine | Biotech Hunter | Biotech Hunter